Innovating Bacterial Vaccines to Protect Humankind
Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the Company’s cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, Vaxcyte’s system for producing difficult-to-make protein antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.
Vaxcyte’s pneumococcal conjugate vaccine (PCV) franchise candidates include VAX-31, a 31-valent PCV candidate advancing to a Phase 3 adult clinical program and currently being evaluated in a Phase 2 infant clinical program, and VAX-24, a 24-valent PCV candidate currently being evaluated in a Phase 2 infant clinical program. VAX-31 and VAX-24 are being studied for the prevention of invasive pneumococcal disease (IPD), which is especially serious in infants, young children, older adults and those with immune deficiencies or certain chronic health conditions. IPD is associated with high case-fatality rates, antibiotic resistance and meningitis. VAX-31 is the broadest-spectrum PCV in the clinic and was designed to increase coverage, in a single vaccine, to more than 95% of IPD circulating in adults in the United States aged 50 and older. In infants, VAX-31 is designed to cover approximately 94% of IPD and approximately 93% of acute otitis media due to Streptococcus pneumoniae in children under five years of age in the United States. VAX-24 has the potential to cover more serotypes than any infant pneumococcal vaccine on-market today.
Vaxcyte’s early-stage pipeline includes VAX-A1, a prophylactic vaccine candidate designed to prevent disease caused by Group A Strep, and VAX-GI, a vaccine candidate designed as a preventative treatment for dysentery and shigellosis, which is caused by Shigella bacteria. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.
Stock Quote
Minimum 15 minutes delayed. Source: LSEG
